LeMaitre Vascular (NASDAQ:LMAT) Lowered to Hold Rating by Zacks Research

Zacks Research cut shares of LeMaitre Vascular (NASDAQ:LMAT) from a strong-buy rating to a hold rating in a report published on Thursday morning,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Wells Fargo & Company decreased their price objective on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research report on Monday, November 10th. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Monday. Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.20.

LeMaitre Vascular Stock Down 1.1%

Shares of LeMaitre Vascular stock opened at $80.17 on Thursday. The business has a 50-day moving average price of $85.25 and a 200 day moving average price of $87.23. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $105.55. The firm has a market cap of $1.82 billion, a P/E ratio of 34.56, a P/E/G ratio of 1.80 and a beta of 0.68. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The company had revenue of $61.05 million for the quarter, compared to the consensus estimate of $62.18 million. During the same quarter last year, the business posted $0.49 EPS. LeMaitre Vascular’s quarterly revenue was up 11.4% compared to the same quarter last year. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. On average, sell-side analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th were paid a $0.20 dividend. The ex-dividend date was Thursday, November 20th. This represents a $0.80 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.48%.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently made changes to their positions in LMAT. Tudor Investment Corp ET AL acquired a new stake in LeMaitre Vascular in the 3rd quarter valued at approximately $6,056,000. CIBC Bancorp USA Inc. acquired a new position in shares of LeMaitre Vascular during the third quarter valued at $799,000. Advisory Services Network LLC bought a new stake in shares of LeMaitre Vascular during the third quarter valued at about $98,000. PharVision Advisers LLC acquired a new stake in LeMaitre Vascular in the third quarter worth about $355,000. Finally, Verition Fund Management LLC grew its position in LeMaitre Vascular by 136.2% in the 3rd quarter. Verition Fund Management LLC now owns 16,907 shares of the medical instruments supplier’s stock valued at $1,480,000 after buying an additional 9,750 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.